Stereotactic ablative radiotherapy in the treatment of early-stage lung cancer - a done deal?
Gulstene, S. Ruwanpura, T Palma, D. Joseph, N.
Gulstene, S.
Ruwanpura, T
Palma, D.
Joseph, N.
Citations
Altmetric:
Abstract
Stereotactic ablative radiotherapy (SABR) is an important curative-intent treatment option for early-stage non-small cell lung cancer. It offers good cancer control without invasive surgery and has become the standard of care for medically inoperable patients. The literature on SABR for early-stage non-small cell lung cancer is substantial and continues to grow. However, there remain areas of controversy where data are limited - notably the use of SABR in medically operable patients. Other areas of some debate include the treatment of central/ultra-central and large (>5 cm) lesions, as well as treatment with co-existing interstitial lung disease. This review article provides an overview of the current literature together with a discussion of future directions.
Authors
Description
Date
2022
Publisher
Collections
Keywords
Type
Article
Citation
Gulstene S, Ruwanpura T, Palma D, Joseph N. Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage Lung Cancer - A Done Deal? Clinical oncology (Royal College of Radiologists (Great Britain)). 2022 Aug 29. PubMed PMID: 36050221. Epub 2022/09/02. eng.